1. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study
- Author
-
Oguz Aktas, Ufuk Yilmaz, Idilhan Ar, Halil İbrahim Yakar, Alev Gürgün, Aylin Konya, Hakan Günen, Mehmet Yilmaz, Mediha Gonenc Ortakoylu, Muge Otlu, Aykut Cilli, Atike Demir, Pelin Duru Cetinkaya, Nurdan Kokturk, Ipek Candemir, Pınar Ergün, and Ege Üniversitesi
- Subjects
physician adherence ,Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Exacerbation ,Turkey ,Cross-sectional study ,Muscarinic Antagonists ,International Journal of Chronic Obstructive Pulmonary Disease ,Severity of Illness Index ,Pulmonary Disease, Chronic Obstructive ,Adrenal Cortex Hormones ,Predictive Value of Tests ,Severity of illness ,Administration, Inhalation ,Prevalence ,Medicine ,Humans ,exacerbation risk ,Practice Patterns, Physicians' ,Adrenergic beta-2 Receptor Agonists ,Lung ,Original Research ,Aged ,Aged, 80 and over ,COPD ,business.industry ,General Medicine ,Recovery of Function ,Middle Aged ,medicine.disease ,Obstructive lung disease ,respiratory tract diseases ,Bronchodilator Agents ,Regimen ,Cross-Sectional Studies ,Treatment Outcome ,combined COPD assessment ,Predictive value of tests ,Cohort ,Practice Guidelines as Topic ,Disease Progression ,symptoms ,Drug Therapy, Combination ,Female ,Guideline Adherence ,business - Abstract
WOS: 000366030500001, PubMed ID: 26622176, Objective: To determine distribution of COPD assessment categories and physicians' adherence to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 strategy in Turkish COPD patients. Methods: A total of 1,610 COPD patients (mean [standard deviation] age: 62.6 [9.9] years, 85.7% were males) were included in this multicenter, non-interventional, cross-sectional study. Patients were categorized via GOLD 2013 strategy document. Consistency between reported and re-classified GOLD categories, and measures used for symptom evaluation and exacerbation was analyzed. Results: Overall, 41.1% of patients were assigned to GOLD A, while 13.2% were assigned to GOLD C categories. Long-acting beta-2 agonist + long-acting muscarinic antagonist + inhaled corticosteroid regimen was the most common treatment (62.0%). Over-treatment was noted in > 70% of GOLD A, B, and C patients. A high consistency between measures of symptom evaluation (Kappa coefficient = 0.993, P < 0.0001) and a low-moderate consistency between exacerbation risk measures (Kappa coefficient = 0.237, P < 0.0001) were noted. Conclusion: Our findings revealed GOLD A as the most prevalent category in Turkish cohort of COPD patients. Group assignment was altered depending on the chosen measure for symptom and risk assessment. Physician non-adherence to treatment recommendations in GOLD 2013 document leading to over-treatment in patients assigned to GOLD A, B, and C categories was also detected., Novartis Pharmaceuticals Turkey, The study is funded by Novartis Pharmaceuticals Turkey. We thank Cagla Ayhan, MD and Prof Sule Oktay, MD, PhD from KAPPA Consultancy Training Research Ltd, Istanbul who provided editorial support and Mehmet Berktas, MD, MICR from KAPPA Consultancy Training Research Ltd, Istanbul who performed statistical analysis funded by Novartis Pharmaceuticals Turkey.
- Published
- 2015